Int J Biol Sci 2023; 19(2):658-674. doi:10.7150/ijbs.77994 This issue Cite

Review

Targeting Necroptosis: A Novel Therapeutic Option for Retinal Degenerative Diseases

Qi Zhang1,2, Xi-min Hu1, Wen-juan Zhao1, Xiao-xia Ban1, Yan Li1, Yan-xia Huang1, Hao Wan1, Ye He3, Lv-shuang Liao4, Lei Shang5, Bin Jiang6, Guo-ping Qing7,8, Kun Xiong1,2,9✉

1. Department of Anatomy and Neurobiology, School of Basic Medical Sciences, Central South University, Changsha, China.
2. Key Laboratory of Emergency and Trauma, Ministry of Education, College of Emergency and Trauma, Hainan Medical University, Haikou, China.
3. Changsha Aier Eye Hospital, Changsha, China.
4. School of Physical Education, Hunan Institute of Science and Technology, Yueyang, China.
5. Affiliated Eye Hospital of Nanchang University, Jiangxi Research Institute of Ophthalmology and Visual Science, Jiangxi Clinical Research Center for Ophthalmic Disease, Nanchang, China.
6. Department of Ophthalmology, The Second Xiangya Hospital, Central South University, Changsha, China.
7. Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
8. Beijing Ophthalmology and Visual Sciences Key Laboratory, Beijing, China.
9. Hunan Key Laboratory of Ophthalmology, Changsha, China.

Citation:
Zhang Q, Hu Xm, Zhao Wj, Ban Xx, Li Y, Huang Yx, Wan H, He Y, Liao Ls, Shang L, Jiang B, Qing Gp, Xiong K. Targeting Necroptosis: A Novel Therapeutic Option for Retinal Degenerative Diseases. Int J Biol Sci 2023; 19(2):658-674. doi:10.7150/ijbs.77994. https://www.ijbs.com/v19p0658.htm
Other styles

File import instruction

Abstract

Graphic abstract

The discovery of the necroptosis, a form of regulated necrosis that is mediated by receptor-interacting protein kinase 1 (RIPK1), RIPK3, and mixed-lineage kinase domain-like pseudokinase (MLKL), represents a major breakthrough that has dramatically altered the conception of necrosis - traditionally thought of as uncontrolled cell death - in various human diseases. Retinal cell death is a leading cause of blindness and has been identified in most retinal diseases, e.g., age-related macular degeneration, glaucoma, retinal detachment, retinitis pigmentosa, etc. Increasing evidence demonstrates that retinal degenerative diseases also share a common mechanism in necroptosis. Exacerbated necroptotic cell death hinders the treatment for retinal degenerative diseases. In this review, we highlight recent advances in identifying retinal necroptosis, summarize the underlying mechanisms of necroptosis in retinal degenerative diseases, and discuss potential anti-necroptosis strategies, such as selective inhibitors and chemical agents, for treating retinal degenerative diseases.

Keywords: Retinal degenerative diseases, necroptosis, RIPK1, RIPK3, age-related macular degeneration, glaucoma


Citation styles

APA
Zhang, Q., Hu, X.m., Zhao, W.j., Ban, X.x., Li, Y., Huang, Y.x., Wan, H., He, Y., Liao, L.s., Shang, L., Jiang, B., Qing, G.p., Xiong, K. (2023). Targeting Necroptosis: A Novel Therapeutic Option for Retinal Degenerative Diseases. International Journal of Biological Sciences, 19(2), 658-674. https://doi.org/10.7150/ijbs.77994.

ACS
Zhang, Q.; Hu, X.m.; Zhao, W.j.; Ban, X.x.; Li, Y.; Huang, Y.x.; Wan, H.; He, Y.; Liao, L.s.; Shang, L.; Jiang, B.; Qing, G.p.; Xiong, K. Targeting Necroptosis: A Novel Therapeutic Option for Retinal Degenerative Diseases. Int. J. Biol. Sci. 2023, 19 (2), 658-674. DOI: 10.7150/ijbs.77994.

NLM
Zhang Q, Hu Xm, Zhao Wj, Ban Xx, Li Y, Huang Yx, Wan H, He Y, Liao Ls, Shang L, Jiang B, Qing Gp, Xiong K. Targeting Necroptosis: A Novel Therapeutic Option for Retinal Degenerative Diseases. Int J Biol Sci 2023; 19(2):658-674. doi:10.7150/ijbs.77994. https://www.ijbs.com/v19p0658.htm

CSE
Zhang Q, Hu Xm, Zhao Wj, Ban Xx, Li Y, Huang Yx, Wan H, He Y, Liao Ls, Shang L, Jiang B, Qing Gp, Xiong K. 2023. Targeting Necroptosis: A Novel Therapeutic Option for Retinal Degenerative Diseases. Int J Biol Sci. 19(2):658-674.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image